Axitinib-LuciAxi

What it treats:

 Small-molecule tyrosine kinase inhibitor (TKI) that mainly targets vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3)

Advanced Renal Cell Carcinoma (RCC)

Used in adults with advanced kidney cancer, typically after failure of one prior systemic therapy (such as sunitinib or cytokine therapy).

Thrombocytopenia in Chronic Hepatitis C

It’s used in adults with chronic ITP who have had an insufficient response to previous treatments (e.g., corticosteroids, immunoglobulins). Avatrombopag helps maintain platelet counts to reduce the risk of bleeding.

Severe Aplastic Anemia (SAA)

Eltrombopag is approved for adults and children (aged 2 and older) with severe aplastic anemia who have had an inadequate response to immunosuppressive therapy. It stimulates bone marrow to improve platelet counts and, in some cases, other blood cell counts.